ReviewClinical pharmacokinetics1994
Clinical pharmacokinetics during continuous haemofiltration.
Review in Clinical pharmacokinetics, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Anti-infective Medicines Use in Children and Neonates With Pre-existing Kidney Dysfunction: A Systematic Review.Frontiers in pediatrics · 2022Pooled it
- Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.Antimicrobial agents and chemotherapy · 2005Trial
- Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.Antimicrobial agents and chemotherapy · 2001Trial
- Pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration.Antimicrobial agents and chemotherapy · 1999Trial
- Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.Antimicrobial agents and chemotherapy · 1997Trial
- Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system.BMC nephrology · 2014Article
- Effect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrations.Antimicrobial agents and chemotherapy · 2012Article
- Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2010Article
- Review
- Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria.The Annals of pharmacotherapy · 2009Review
- Adsorption of amikacin, a significant mechanism of elimination by hemofiltration.Antimicrobial agents and chemotherapy · 2008Article
- Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.Clinical pharmacokinetics · 2006Review
- Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.British journal of clinical pharmacology · 2004Article
- Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.Paediatric drugs · 2004Review
- Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.Antimicrobial agents and chemotherapy · 2001Article
- Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.Antimicrobial agents and chemotherapy · 2000Article
- Drug therapy in haemodialysis patients. Special considerations in the elderly.Drugs & aging · 1998Review
- Principles of drug administration in renal insufficiency.Clinical pharmacokinetics · 1997Review
- Review
- Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAGArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Continuous haemofiltration is an extracorporeal technique that is increasingly used to remove fluid, electrolytes, and other waste products from the blood supply of critically ill patients with acute renal failure. Continuous arteriovenous haemofiltration (CAVH), where the blood exits the body from an artery and re-enters through a vein, is widely used. Continuous venovenous haemofiltration (CVVH), where blood both exits and enters through a vein by way of a mechanical pump, avoids problems that result from the variable ultrafiltration rate found during CAVH. Continuous arteriovenous or venovenous haemodiafiltration (CAVHD or CVVHD) combine continuous haemofiltration and haemodialysis. All methods involve ultrafiltration of the patient's blood through a filter that is highly permeable to water and small molecules. Drug elimination by haemofiltration depends mainly on the rate of ultrafiltration, the drug protein binding and the sieving coefficient of the membrane. Because patients undergoing continuous haemofiltration have impaired renal function, dosage reduction is often recommended so that adverse drug reactions are avoided. In contrast, if drug removal by haemofiltration is significant, dosage supplementation may be required to ensure therapeutic efficacy of the drug. Therefore, knowledge of the impact of continuous haemofiltration on drug elimination and the pharmacokinetic profile of drugs is essential to good clinical management. The currently available information on the clinical pharmacokinetic aspects of drug therapy during continuous haemofiltration are summarised. Drugs commonly associated with haemofiltration therapy are tabulated with updated pharmacokinetics and drug-monitoring information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.